OBJECTIVE: To compare the physiological parameters, arterial blood gas values, induction quality, and recovery quality after IV injection of alfaxalone or propofol in dogs. STUDY DESIGN: Prospective, randomized, blinded crossover. ANIMALS: Eight random-source adult female mixed-breed dogs weighing 18.7 ± 4.5 kg. METHODS: Dogs were assigned to receive up to 8 mg kg(-1) propofol or 4 mg kg(-1) alfaxalone, administered to effect, at 10% of the calculated dose every 10 seconds. They then received the alternate drug after a 6-day washout. Temperature, pulse rate, respiratory rate, direct blood pressure, and arterial blood gases were measured before induction, immediately post-induction, and at 5-minute intervals until extubation. Quality of induction, recovery, and ataxia were scored by a single blinded investigator. Duration of anesthesia and recovery, and adverse events were recorded. RESULTS: The mean doses required for induction were 2.6 ± 0.4 mg kg(-1) alfaxalone and 5.2 ± 0.8 mg kg(-1) propofol. After alfaxalone, temperature, respiration, and pH were significantly lower, and PaCO2 significantly higher post-induction compared to baseline (p < 0.03). After propofol, pH, PaO2 , and SaO2 were significantly lower, and PaCO2 , HCO3 , and PA-aO2 gradient significantly higher post-induction compared to baseline (p < 0.03). Post-induction and 5-minute physiologic and blood gas values were not significantly different between alfaxalone and propofol. Alfaxalone resulted in significantly longer times to achieve sternal recumbency (p = 0.0003) and standing (p = 0.0004) compared to propofol. Subjective scores for induction, recovery, and ataxia were not significantly different between treatments; however, dogs undergoing alfaxalone anesthesia were more likely to have ≥ 1 adverse event (p = 0.041). There were no serious adverse events in either treatment. CONCLUSIONS AND CLINICAL RELEVANCE: There were no clinically significant differences in cardiopulmonary effects between propofol and alfaxalone. A single bolus of propofol resulted in shorter recovery times and fewer adverse events than a single bolus of alfaxalone.
OBJECTIVE: To compare the physiological parameters, arterial blood gas values, induction quality, and recovery quality after IV injection of alfaxalone or propofol in dogs. STUDY DESIGN: Prospective, randomized, blinded crossover. ANIMALS: Eight random-source adult female mixed-breed dogs weighing 18.7 ± 4.5 kg. METHODS:Dogs were assigned to receive up to 8 mg kg(-1) propofol or 4 mg kg(-1) alfaxalone, administered to effect, at 10% of the calculated dose every 10 seconds. They then received the alternate drug after a 6-day washout. Temperature, pulse rate, respiratory rate, direct blood pressure, and arterial blood gases were measured before induction, immediately post-induction, and at 5-minute intervals until extubation. Quality of induction, recovery, and ataxia were scored by a single blinded investigator. Duration of anesthesia and recovery, and adverse events were recorded. RESULTS: The mean doses required for induction were 2.6 ± 0.4 mg kg(-1) alfaxalone and 5.2 ± 0.8 mg kg(-1) propofol. After alfaxalone, temperature, respiration, and pH were significantly lower, and PaCO2 significantly higher post-induction compared to baseline (p < 0.03). After propofol, pH, PaO2 , and SaO2 were significantly lower, and PaCO2 , HCO3 , and PA-aO2 gradient significantly higher post-induction compared to baseline (p < 0.03). Post-induction and 5-minute physiologic and blood gas values were not significantly different between alfaxalone and propofol. Alfaxalone resulted in significantly longer times to achieve sternal recumbency (p = 0.0003) and standing (p = 0.0004) compared to propofol. Subjective scores for induction, recovery, and ataxia were not significantly different between treatments; however, dogs undergoing alfaxalone anesthesia were more likely to have ≥ 1 adverse event (p = 0.041). There were no serious adverse events in either treatment. CONCLUSIONS AND CLINICAL RELEVANCE: There were no clinically significant differences in cardiopulmonary effects between propofol and alfaxalone. A single bolus of propofol resulted in shorter recovery times and fewer adverse events than a single bolus of alfaxalone.